Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Study Looks At HIV, Risk Behaviors Among Male Clients Of Sex Workers In Tijuana, Mexico
"A large percentage" of U.S. and Mexican men who regularly engage in sexual activity with sex workers in Tijuana, Mexico, do not use condoms and have a history of substance and alcohol use, according to a study published in the online journal AIDS, the Los Angeles Times" blog "L.A. Now" reports. The study, by researchers from Mexico and the University of California-San Diego, surveyed 400 men - both Mexico and U.S. residents - and found that half of the men had unprotected sex with a female sex worker within the last four months. Researchers noted that although Tijuana authorities require that sex workers be registered and tested regularly for HIV, "only about half of [sex workers] have registered or been tested," according to the blog. Thomas Patterson of the UC-San Diego"s department of psychiatry and the Veterans Affairs health center, said the findings indicate a need for an educational campaign targeting men who frequent sex workers (Perry, 7/11).

First Human Demonstration Of Significant, Persistent Antibody Response Using Electroporation-Delivered DNA Vaccine Published In Human Gene Therapy
Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today new data representing what Inovio believes to be the first demonstration of a significantly increased and persistent level of antibody response generated by a DNA vaccine delivered using electroporation.
News of the day
Cancer Therapies: How Much Is Life Worth? The $440 Billion Question
The decision to use expensive cancer therapies that typically produce only a relatively short extension of survival is a serious ethical dilemma in the U.S. that needs to be addressed by the oncology community, according to a commentary published online June 29 in the Journal of the National Cancer Institute.
Nutrition

Sinovac Completes Construction Of H1N1 Virus Seed Bank

Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, announced today that it has completed construction of the H1N1 virus seed bank necessary to produce a virus antigen. Sinovac received the seed virus from the US Center for Disease Control (CDC) on June 8, 2009 and started the H1N1 vaccine production on the same day. Sinovac expects to complete production of the first batch and initiate clinical trials of an H1N1 vaccine by the end of July 2009. Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "On June 11, 2009, the World Health Organization declared the H1N1 virus a pandemic influenza outbreak. Having completed the construction of our virus seed bank, our H1N1 vaccine production remains on track and we look forward to initiating clinical trials by the end of next month. Sinovac"s rapid response to the newly emerged disease outbreak demonstrates the Company"s res and capabilities for vaccine production and highlights our commitment to protect the public from virus transmission through the timely supply of vaccines." Sinovac"s production of Anflu for the 2009/2010 Northern Hemisphere influenza season is nearly completed. The production of H1N1 vaccine will not affect its production and launch of the seasonal flu vaccine for this coming flu season. About Sinovac Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac"s vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac"s pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis vaccine, and human rabies vaccine. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines. Safe Harbor Statement This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac"s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law. Sinovac Biotech Ltd


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009